AP
AXSM icon

AtonRa Partners’s Axsome Therapeutics AXSM Stock Holding History

AtonRa Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$372K Sell
4,678
-502
-10% -$33.6K 0.74% 57
2023
Q3 		$362K Buy
+5,180
New +$387K 0.76% 63

Other funds holding AXSM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AtonRa Partners's AXSM Position: Q4 2023 in Review

AtonRa Partners reduced its Axsome Therapeutics (AXSM) stake by 9.7% in Q4 2023, selling an estimated $33.6K and leaving 4,678 shares worth $372K. The position accounts for 0.74% of the portfolio, ranked #57.

AtonRa Partners first reported a position in AXSM in Q3 2023 and has held it in 2 quarters since. 244 funds tracked by Wall St. Rank hold AXSM as of Q4 2023.

  • AtonRa Partners held 4,678 shares of Axsome Therapeutics worth $372K as of Q4 2023.
  • AtonRa Partners sold 502 Axsome Therapeutics shares in Q4 2023, an estimated $33.6K.
  • Axsome Therapeutics made up 0.74% of AtonRa Partners's portfolio in Q4 2023, its #57 holding.
  • AtonRa Partners first reported a position in Axsome Therapeutics in Q3 2023 and has held it in 2 quarters since.
  • 244 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2023.

Based on AtonRa Partners's 13F filing for Q4 2023, filed 5 Feb 2024.